Kinetics of human peptidylarginine deiminase 2 (hPAD2) - Reduction of Ca2+ dependence by phospholipids and assessment of proposed inhibition by paclitaxel side chains

Biochemistry and Cell Biology

Volumn 86, Issue 5, 2008, Pages 437-447

  Musse, Abdiwahab A ^a   Polverini, Eugenia ^b   Raijmakers, Reinout ^c   Harauz, George ^a  

^a UNIVERSITY OF GUELPH   (Canada)

^b UNIVERSITY OF PARMA   (Italy)

^c UTRECHT UNIVERSITY   (Netherlands)

Author keywords

Citrulline; Deimination; Multiple sclerosis; Myelin; Myelin basic protein; Paclitaxel; Paclitaxel side chain; Peptidylarginine deiminase; Post translational modifications

Indexed keywords

AMINO ACIDS; CALCIUM; CELL MEMBRANES; ENZYMES; ESTERIFICATION; ESTERS; ORGANIC COMPOUNDS; PHOSPHOLIPIDS; PROTEINS;

CITRULLINE; DEIMINATION; MULTIPLE SCLEROSIS; MYELIN; MYELIN BASIC PROTEIN; PACLITAXEL; PACLITAXEL SIDE CHAIN; PEPTIDYLARGININE DEIMINASE; POST-TRANSLATIONAL MODIFICATIONS;

ENZYME ACTIVITY;

BENZOYLARGININE ETHYL ESTER; CITRULLINE; ISOENZYME; MYELIN; MYELIN BASIC PROTEIN; PACLITAXEL; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLSERINE; PHOSPHOLIPID; PROTEIN ARGININE DEIMINASE; PROTEIN ARGININE DEIMINASE 2; UNCLASSIFIED DRUG;

ARTICLE; BINDING AFFINITY; CATALYSIS; CENTRAL NERVOUS SYSTEM; COMPUTER MODEL; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DEGENERATIVE DISEASE; DRUG STRUCTURE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; ENZYME INHIBITION; ENZYME STRUCTURE; INHIBITION KINETICS; MOLECULAR DOCKING; MYELIN SHEATH; NONHUMAN; PROTEIN PROCESSING; SEQUENCE HOMOLOGY;

AMINO ACID SEQUENCE; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CALCIUM; CATALYTIC DOMAIN; HUMANS; HYDROLASES; ISOENZYMES; KINETICS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; MOLECULAR STRUCTURE; MULTIPLE SCLEROSIS; PACLITAXEL; PHOSPHOLIPIDS; PROTEIN CONFORMATION; SEQUENCE ALIGNMENT;

EID: 54249134964     PISSN: 08298211     EISSN: None     Source Type: Journal    
DOI: 10.1139/O08-124     Document Type: Article

References (56)

1. Akiyama, K., Sakurai, Y., Asou, H., and Senshu, T. 1999. Localization of peptidylarginine deiminase type II in a stage-specific immature oligodendrocyte from rat cerebral hemisphere. Neurosci. Lett. 274: 53-55. doi:10.1016/S0304-3940(99)00678-3. PMID:10530518.
2. Arita, K., Hashimoto, H., Shimizu, T., Yamada, M., and Sato, M. 2003. Crystallization and preliminary X-ray crystallographic analysis of human peptidylarginine deiminase V. Acta Crystallogr. Sect. D: Biol. Crystallogr. 59: 2332-2333. doi:10.1107/S0907444903022741. PMID:14646111.
3. 2+-induced activation of human PAD4. Nat. Struct. Mol. Biol. 11: 777-783. doi:10.1038/nsmb799. PMID:15247907.
4. Arita, K., Shimizu, T., Hashimoto, H., Hidaka, Y., Yamada, M., and Sato, M. 2006. Structural basis for histone N-terminal recognition by human peptidylarginine deiminase 4. Proc. Natl. Acad. Sci. U.S.A. 103: 5291-5296. doi:10.1073/pnas. 0509639103. PMID:16567635.
5. Asaga, H., and Ishigami, A. 2007. Microglial expression of peptidylarginine deiminase 2 in the prenatal rat brain. Cell. Mol. Biol. Lett. 12: 536-544. doi:10.2478/s11658-007-0025-y. PMID:17579814.
6. Asaga, H., Akiyama, K., Ohsawa, T., and Ishigami, A. 2002. Increased and type II-specific expression of peptidylarginine deiminase in activated microglia but not hyperplastic astrocytes following kainic acid-evoked neurodegeneration in the rat brain. Neurosci. Lett. 326: 129-132. doi:10.1016/S0304- 3940(02)00334-8. PMID:12057845.
7. Balandraud, N., Gouret, P., Danchin, E.G., Blanc, M., Zinn, D., Roudier, J., and Pontarotti, P. 2005. A rigorous method for multigenic families' functional annotation: the peptidyl arginine deiminase (PADs) proteins family example. BMC Genomics, 6: 153. doi:10.1186/1471-2164-6-153. PMID:16271148.
8. Berman, H.M., Westbrook, J., Feng, Z., Gilliland, G., Bhat, T.N., Weissig, H., et al. 2000. The Protein Data Bank. Nucleic Acids Res. 28: 235-242. doi:10.1093/nar/28.1.235. PMID:10592235.
9. Bhattacharya, S.K., Bhat, M.B., and Takahara, H. 2006. Modulation of peptidyl arginine deiminase 2 and implication for neurodegeneration. Curr. Eye Res. 31: 1063-1071. doi:10.1080/02713680600991437. PMID:17169845.
10. Chavanas, S., Mechin, M.C., Nachat, R., Adoue, V., Coudane, F., Serre, G., and Simon, M. 2006. Peptidylarginine deiminases and deimination in biology and pathology: relevance to skin homeostasis. J. Dermatol. Sci. 44: 63-72. doi:10.1016/j.jdermsci.2006.07.004. PMID:16973334.
11. Chen, P.S., Toribara, T.Y., and Warner, H. 1956. Microdetermination of phosphorus. Anal. Chem. 28: 1756-1758. doi:10.1021/ac60119a033.
12. Clark, M., Cramer, R.D., and Vanopdenbosch, N. 1989. Validation of the general-purpose Tripos 5.2 force-field. J. Comput. Chem. 10: 982-1012. doi:10.1002/jcc.540100804.
13. DeBruin, L.S., and Harauz, G. 2007. White matter rafting - membrane microdomains in myelin. Neurochem. Res. 32: 213-228. doi:10.1007/s11064- 006-9137-4. PMID:17031566.
14. DeBruin, L.S., Haines, J.D., Bienzle, D., and Harauz, G. 2006. Partitioning of myelin basic protein into membrane microdomains in a spontaneously demyelinating mouse model for multiple sclerosis. Biochem. Cell Biol. 84: 993-1005. doi:10.1139/O06-180. PMID:17215885.
15. Ehrlich, A., Booher, S., Becerra, Y., Borris, D.L., Figg, W.D., Turner, M.L., and Blauvelt, A. 2004. Micellar paclitaxel improves severe psoriasis in a prospective phase II pilot study. J. Am. Acad. Dermatol. 50: 533-540. doi:10.1016/j.jaad.2003.09.018. PMID: 15034502.
16. Harauz, G., and Musse, A.A. 2007. A tale of two citrullines - Structural and functional aspects of myelin basic protein deimination in health and disease. Neurochem. Res. 32: 137-158. doi:10.1007/s11064-006-9108-9. PMID:16900293.
17. Humphrey, W., Dalke, A., and Schulten, K. 1996. VMD: visual molecular dynamics. J. Mol. Graph. 14: 33-38. doi:10.1016/0263-7855(96)00018-5. PMID:8744570.
18. Iwamoto, T., Ikari, K., Nakamura, T., Kuwahara, M., Toyama, Y., Tomatsu, T., et al. 2006. Association between PADI4 and rheumatoid arthritis: a meta-analysis. Rheumatology (Oxford), 45: 804-807. doi:10.1093/ rheumatology/kel023. PMID:16449362.
19. Kearney, P.L., Bhatia, M., Jones, N.G., Yuan, L., Glascock, M.C., Catchings, K.L., et al. 2005. Kinetic characterization of protein arginine deiminase 4: a transcriptional corepressor implicated in the onset and progression of rheumatoid arthritis. Biochemistry, 44: 10570-10582. doi:10.1021/bi050292m. PMID:16060666.
20. Kim, J.K., Mastronardi, F.G., Wood, D.D., Lubman, D.M., Zand, R., and Moscarello, M.A. 2003. Multiple sclerosis: an important role for post-translational modifications of myelin basic protein in pathogenesis. Mol. Cell. Proteomics, 2: 453-462. doi:10.1074/mcp.M200050-MCP200. PMID: 12832457.
21. Knuckley, B., Luo, Y., and Thompson, P.R. 2008. Profiling protein arginine deiminase 4 (PAD4): a novel screen to identify PAD4 inhibitors. Bioorg. Med. Chem. 16: 739-745. doi:10.1016/j.bmc.2007.10.021. PMID:17964793.
22. Kubilus, J., and Baden, H.P. 1983. Purification and properties of a brain enzyme which deiminates proteins. Biochim. Biophys. Acta, 745: 285-291. PMID:6860676.
23. Lamensa, J.W., and Moscarello, M.A. 1993. Deimination of human myelin basic protein by a peptidylarginine deiminase from bovine brain. J. Neurochem. 61: 987-996. doi:10.1111/j.1471-4159.1993.tb03612.x. PMID:7689646.
24. Luo, Y., Arita, K., Bhatia, M., Knuckley, B., Lee, Y.H., Stallcup, M.R., et al. 2006a. Inhibitors and inactivators of protein arginine deiminase 4: functional and structural characterization. Biochemistry, 45: 11727-11736. doi:10.1021/bi061180d. PMID: 17002273.
25. Luo, Y., Knuckley, B., Lee, Y.H., Stallcup, M.R., and Thompson, P.R. 2006b. A fluoroacetamidine-based inactivator of protein arginine deiminase 4: design, synthesis, and in vitro and in vivo evaluation. J. Am. Chem. Soc. 128: 1092-1093. doi:10.1021/ja0576233. PMID:16433522.
26. Mastronardi, F.G., and Moscarello, M.A. 2005. Molecules affecting myelin stability: a novel hypothesis regarding the pathogenesis of multiple sclerosis. J. Neurosci. Res. 80: 301-308. doi:10.1002/jnr.20420. PMID:15704220.
27. Mastronardi, F.G., Ackerley, C.A., Roots, B.I., and Moscarello, M.A. 1996a. Loss of myelin basic protein cationicity in DM20 transgenic mice is dosage dependent. J. Neurosci. Res. 44: 301-307. doi:10.1002/(SICI) 1097-4547(19960515)44:4∠301::AID-JNR1〉3.0.CO;2-G. PMID:8739149.
28. Mastronardi, F.G., Mak, B., Ackerley, C.A., Roots, B.I., and Moscarello, M.A. 1996b. Modifications of myelin basic protein in DM20 transgenic mice are similar to those in myelin basic protein from multiple sclerosis. J. Clin. Invest. 97: 349-358. doi:10.1172/JCI118422. PMID:8567954.
29. Mastronardi, F.G., Wood, D.D., Mei, J., Raijmakers, R., Tseveleki, V., Dosch, H.M., et al. 2006. Increased citrullination of histone H3 in multiple sclerosis brain and animal models of demyelination: a role for tumor necrosis factor-induced peptidylarginine deiminase 4 translocation. J. Neurosci. 26: 11387-11396. doi:10.1523/JNEUROSCI.3349-06.2006. PMID:17079667.
30. Mastronardi, F.G., Tsui, H., Winer, S., Wood, D.D., Selvanantham, T., Galligan, C., et al. 2007. Synergy between paclitaxel plus an exogenous methyl donor in the suppression of murine demyelinating diseases. Mult. Scler. 13: 596-609. doi:10.1177/1352458506072167. PMID:17548438.
31. Matesanz, R., Barasoain, I., Yang, C.G., Wang, L., Li, X., de Ines, C., et al. 2008. Optimization of taxane binding to microtubules: binding affinity dissection and incremental construction of a high-affinity analog of paclitaxel. Chem. Biol. 15: 573-585. doi:10.1016/j.chembiol.2008.05.008. PMID:18559268.
32. Mechin, M.C., Sebbag, M., Arnaud, J., Nachat, R., Foulquier, C., Adoue, V., et al. 2007. Update on peptidylarginine deiminases and deimination in skin physiology and severe human diseases. Int. J. Cosmet. Sci. 29: 147-168. doi:10.1111/j.1467-2494.2007.00377.x. PMID:18489346.
33. Micu, I., Jiang, Q., Coderre, E., Ridsdale, A., Zhang, L., Woulfe, J., et al. 2006. NMDA receptors mediate calcium accumulation in myelin during chemical ischaemia. Nature, 439: 988-992. PMID:16372019.
34. 2+ changes in CNS myelin by two-photon microscopy. Nat. Med. 13: 874-879. doi:10.1038/nm1568. PMID:17603496.
35. Morris, G.M., Goodsell, D.S., Halliday, R.S., Huey, R., Hart, W.E., Below, R.K., and Olson, A.J. 1998. Automated docking using a Lamarckian genetic algorithm and an empirical binding free energy function. J. Comput. Chem. 19: 1639-1662. doi:10.1002/(SICI)1096-987X(19981115)19:14〈1639::AID- JCC10〉3.0.CO;2-B.
36. Moscarello, M.A., Mak, B., Nguyen, T.A., Wood, D.D., Mastronardi, F., and Ludwin, S.K. 2002a. Paclitaxel (Taxol) attenuates clinical disease in a spontaneously demyelinating transgenic mouse and induces remyelination. Mult. Scler. 8: 130-138. doi:10.1191/1352458502ms776oa. PMID:11990870.
37. Moscarello, M.A., Pritzker, L., Mastronardi, F.G., and Wood, D.D. 2002b. Peptidylarginine deiminase: a candidate factor in demyelinating disease. J. Neurochem. 81: 335-343. doi:10.1046/j.1471-4159.2002.00834.x. PMID:12064481.
38. Musse, A.A., and Harauz, G. 2007. Molecular "negativity" may underlie multiple sclerosis: role of the myelin basic protein family in the pathogenesis of MS. Int. Rev. Neurobiol. 79: 149-172. doi:10.1016/S0074-7742(07)79007-4. PMID:17531841.
39. Musse, A.A., Boggs, J.M., and Harauz, G. 2006. Deimination of membrane-bound myelin basic protein in multiple sclerosis exposes an immunodominant epitope. Proc. Natl. Acad. Sci. U.S.A. 103: 4422-4427. doi:10.1073/pnas.0509158103. PMID: 16537438.
40. Musse, A.A., Li, Z., Ackerley, C.A., Bienzle, D., Lei, H., Poma, R., et al. 2008. Peptidylarginine deiminase 2 (PAD2) expression in a transgenic mouse leads to specific central nervous system (CNS) myelin instability. Disease Models and Mechanisms. Accepted for publication.
41. Nachat, R., Mechin, M.C., Takahara, H., Chavanas, S., Charveron, M., Serre, G., and Simon, M. 2005. Peptidylarginine deiminase isoforms 1-3 are expressed in the epidermis and involved in the deimination of K1 and filaggrin. J. Invest. Dermatol. 124: 384-393. doi:10.1111/j.0022-202X.2004.23568.x. PMID:15675958.
42. Nakayama-Hamada, M., Suzuki, A., Kubota, K., Takazawa, T., Ohsaka, M., Kawaida, R., et al. 2005. Comparison of enzymatic properties between hPADI2 and hPADI4. Biochem. Biophys. Res. Commun. 327: 192-200. doi:10.1016/j.bbrc. 2004.11.152. PMID:15629448.
43. Petrescu, N., Micu, I., Malek, S., Ouardouz, M., and Stys, P.K. 2007. Sources of axonal calcium loading during in vitro ischemia of rat dorsal roots. Muscle Nerve, 35: 451-457. doi:10.1002/mus.20731. PMID:17206661.
44. Pritzker, L.B., and Moscarello, M.A. 1998. A novel microtubule independent effect of paclitaxel: the inhibition of peptidylarginine deiminase from bovine brain. Biochim. Biophys. Acta, 1388: 154-160. PMID:9774721.
45. Pritzker, L.B., Nguyen, T.A., and Moscarello, M.A. 1999. The developmental expression and activity of peptidylarginine deiminase in the mouse. Neurosci. Lett. 266: 161-164. doi:10.1016/S0304-3940(99)00276-1. PMID:10465698.
46. Raijmakers, R., Vogelzangs, J., Raats, J., Panzenbeck, M., Corby, M., Jiang, H., et al. 2006. Experimental autoimmune encephalomyelitis induction in peptidylarginine deiminase 2 knockout mice. J. Comp. Neurol. 498: 217-226. doi:10.1002/cne.21055. PMID:16856138.
47. Raijmakers, R., Zendman, A.J., Egberts, W.V., Vossenaar, E.R., Raats, J., Soede-Huijbregts, C., et al. 2007. Methylation of arginine residues interferes with citrullination by peptidylarginine deiminases in vitro. J. Mol. Biol. 367: 1118-1129. doi:10.1016/j.jmb.2007.01.054. PMID:17303166.
48. Stone, E.M., Schaller, T.H., Bianchi, H., Person, M.D., and Fast, W. 2005. Inactivation of two diverse enzymes in the amidinotransferase superfamily by 2-chloroacetamidine: dimethylargininase and peptidylarginine deiminase. Biochemistry, 44: 13744-13752. doi:10.1021/bi051341y. PMID:16229464.
49. Suzuki, A., Yamada, R., Chang, X., Tokuhiro, S., Sawada, T., Suzuki, M., et al. 2003. Functional haplotypes of PADI4, encoding citrullinating enzyme peptidylarginine deiminase 4, are associated with rheumatoid arthritis. Nat. Genet. 34: 395-402. doi:10.1038/ng1206. PMID:12833157.
50. Takahara, H., Koyama, M., and Sugawara, K. 1987. Subcellular location of peptidylarginine deiminase in the mouse brain. Agric. Biol. Chem. 51: 1471-1473.
51. Thompson, J.D., Higgins, D.G., and Gibson, T.J. 1994. CLUSTAL W: improving the sensitivity of progressive multiple sequence alignment through sequence weighting, position-specific gap penalties, and weight matrix choice. Nucleic Acids Res. 22: 4673-4680. doi:10.1093/nar/22.22.4673. PMID:7984417.
52. Vincent, S.R., Leung, E., and Watanabe, K. 1992. Immunohistochemical localization of peptidylarginine deiminase in the rat brain. J. Chem. Neuroanat. 5: 159-168. doi:10.1016/0891-0618(92)90041-N. PMID:1586471.
53. Vossenaar, E.R., Zendman, A.J., van Venrooij, W.J., and Pruijn, G.J. 2003. PAD, a growing family of citrullinating enzymes: genes, features, and involvement in disease. Bioessays, 25: 1106-1118. doi:10.1002/bies.10357. PMID:14579251.
54. Watanabe, K., Akiyama, K., Hikichi, K., Ohtsuka, R., Okuyama, A., and Senshu, T. 1988. Combined biochemical and immunochemical comparison of peptidylarginine deiminases present in various tissues. Biochim. Biophys. Acta, 966: 375-383. PMID: 3416014.
55. Wood, D.D., Ackerley, C.A., Brand, B., Zhang, L., Raijmakers, R., Mastronardi, F.G., and Moscarello, M.A. 2008. Myelin localization of peptidylarginine deiminases 2 and 4: comparison of PAD2 and PAD4 activities. Lab. Invest. 88: 354-364. doi:10.1038/labinvest.3700748. PMID:18227806.
56. Zendman, A.J., Raijmakers, R., Nijenhuis, S., Vossenaar, E.R., Tillaart, M., Chirivi, R.G., et al. 2007. ABAP: antibody-based assay for peptidylarginine deiminase activity. Anal. Biochem. 369: 232-240. doi:10.1016/j.ab.2007. 07.009. PMID:17716614.